The feasibility and safety of enhanced recovery after surgery combined with laparoscopic in benign gynecologic tumor
10.3760/cma.j.cn115455-20200110-00046
- VernacularTitle:加速康复外科在妇科良性肿瘤腹腔镜手术中应用的可行性和安全性分析
- Author:
Huimin LI
1
;
Beibei HUANG
;
Na FENG
Author Information
1. 安徽省宿州市立医院妇科 234000
- From:
Chinese Journal of Postgraduates of Medicine
2020;43(8):716-720
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the feasibility and safety of enhanced recovery after surgery (ERAS) combined with laparoscopic in benign gynecologic tumor.Methods:The clinical data of 160 patients with benign gynecologic tumor underwent gynecological laparoscopic surgery in Suzhou Municipal Hospital from January 2017 to May 2018 were selected and analyzed. In these patients, 80 patients who underwent ERAS combined with laparoscopic was enrolled in ERAS group, and 80 patients who underwent laparoscopic surgery in traditional model was enrolled in control group. The operation time, intraoperative blood loss, postoperative exhaust time, rate of postoperative complications, the scores of visual analogue scale (VAS) at postoperative 3, 6, 12, 24 h, average hospital stay, and average hospitalization expenses were compared between two groups.Results:The operation time, intraoperative blood loss in two groups had no significant differences ( P>0.05). The rate of postoperative complications in two groups had no significant difference ( P>0.05). The postoperative exhaust time in ERAS group was shorter than that in control group [(9.8 ± 2.7) h vs. (19.1 ± 4.0) h] ( P<0.05). The scores of VAS at postoperative 12, 24 h were lower than those in control group [(1.9 ± 0.7) scores vs. (4.2 ± 0.8) scores, (1.3 ± 0.4) scores vs. (3.5 ± 0.9) scores] ( P<0.05). Four patients in control group were injected with pethidine and no patients in ERAS group used pethidine, and the rate of using pethidine in two groups had significant difference [0 vs. 5.0%(4/80)]( P<0.05). The average hospital stay, average hospitalization expenses in ERAS group were lower than those in control group [(3.9 ± 0.7) d vs. (5.2 ± 0.9) d, (1.1 ± 0.1) ten thousand Yuan vs. (1.3 ± 0.1) ten thousand Yuan] ( P<0.01). Conclusions:The ERAS combined with laparoscopic in benign gynecologic tumor is safe and effective during perioperative period, and is worth of expanding.
